EirGenix is Taiwan's largest contract development and manufacturing organization (CDMO) for mammalian and microbial-derived biologics, providing full, one-stop services from pre-clinical development, CLD, Process Development, Analytical Development, Clinical to CGMP commercial manufacturing. EirGenix has extensive experience with various biologics including monoclonal and bi/poly-specific antibodies, recombinant proteins, antibody-drug conjugates (ADCs), and plasmid DNAs including developing and manufacturing a marketed biosimilar. EirGenix is inspected and approved by the USFDA, Japan PMDA, Australia TGA, and the EU EMA. EirGenix has a current capacity of 12 x 2,000 L SUB for the production using mammalian cells and a 150 L scale fermenter for microbial. In late 2024, our microbial scale will increase to 350L and 1,000L fermenter.